Cannabinoids are the costituents of the marijuana plants. The central effects ofexogenous cannabinoids are implicated in enhancing mood, altering emotional states, and interfering in the formation of short-term memory. Cannabinoid receptors are G protein-coupled receptors with seven transmembrane domains that are expressed on the cell surface with their binding domain exposed to the extracellular space. To date, two cannabinoid receptors have been cloned, CBI and CB2. Recent evidence suggests that a third 'CB3' receptor may be cloned in the near future. The endocannabinoids may represent the first members of a new classes of neuromodulators, that are not stored in cell vesicles, but rather synthesised by the cell on demand. The endogenous cannabinoid system could playa central role in several neuropsychiatric disorders and is also involved in other conditions such as pain, spasticity and neuroprotection. Implication of cannabinoid system in the pathogenesis and development of schizophrenia is also discussed.
Cannabinoids are the costituents of the marijuana plants (cannabis sativa). The plant contains at least 66 cannabinoid compounds, most of which are closely related. Of these ,:l9_ tetrahydrocannabinol (,:l9 -THC) is the primary psychoactive component. The recreational and therapeutic properties of cannabis-derived preparations have been known for centuries. Since Cannabis was noted to have anticonvulsive, analgesic, antianxiety, and antiemetic properties and became widely used for the treatment of dysmenorrhea, cramps, and asthma in the 19 th century. The discovery of alternati ve treatments for these clinical conditions and political pressure led to its use being outlawed in 1971.
Cannabinoid receptors are G protein-coupled receptors with seven transmembrane domains that are expressed on the cell surface with their binding domain exposed to the extracellular space (I ,2). To date, two cannabinoid receptors have been cloned, CB I and CB2. Recent evidence suggests that a third 'CB3' receptor may be cloned. Although CB I receptors are expressed throughout the body, they are particularly abundant in the CNS where no other cannabinoid receptor subtype has yet been found. This is an unusual situation since most neurotransmitters act on multiple CNS receptors. Current data indicate that a single pharmacological site accounts for all central effects of cannabimimetic drugs, whether therapeutically favorable (e.g. analgesia) or harmful (e.g. dysphoria and amnesia). Although potent CB I receptor agonists have been available for some time, the therapeutic development of these compounds has been very limited.
Within the central nervous system, the distribution of the cannabinoid CB I receptor has been extensively documented (3, 4) . CB I receptors are found in many brain regions including cortex, hippocampus, nucleus accumbens, basal ganglia, hypothalamus, amygdala, cerebellum and retina. However, the highest abundance of receptors is in cerebellar, basal ganglia and hippocampal brain regions. This regional distribution corresponds well with the known central effects of cannabinoids, in enhancing mood, altering emotional state, and interfering in the formation of short-term memory. Two endogenous ligands, anandamide (5) and 2arachidonyl glycerol (6), (designated endocannabinoids) have been discovered (see Figure I). These compounds are both arachidonic acid derivates that activate cannabinoid receptors both centrally and peripherally. The endocannabinoids may represent the first members of a new classes of neuromodulators, that are not stored in cell vesicles, but rather synthesised by the cell on demand (7) . The CB I endocannabinoid system regulates synaptic neurotransmission of excitatory and inhibitory circuits (8, 9) . In response to depolarisation and Ca" fluxes, and in some instances, postsynaptic group I metabotrophicglutamate receptor activation, endocannabinoids are released that inhibit further neurotransmitter via stimulation of presynaptic CB I receptors (9) . As a regulatorofneurotransmission, the cannabinoid system seems to influence many different functions. Experimental evidence suggest that cannabinoids affect the activity of most neurotransmitters. The result of receptor after stimulation depends on the location of the receptor within the excitatory or inhibitory neural circuit being stimulated. This may explain the paradoxical findings that cannabis suppresses or induces certain phenotypical signs (e.g., convulsions, tremor) (10) In situ hybridization, immunocytochemical and autoradiographic evidence demonstrates the presence of CB2 receptors in spleen, thymus, tonsils, bone marrow, pancreas. They are also found in splenic macrophage/monocyte preparations, mast cells, peripheral blood leukocytes, and in a variety of cultured immune cell models, these include the myeloid cell line U937, and undifferentiated and differentiated granulocyte-like, as well as macrophage-like HL60 cells (II ,12). CB I receptors are probably involved in mediating effects of cannabinoid receptor agonists in the CNS, but several peripheral effects of cannabimimetic drugs depend only partially on CB I receptor activation. The high expression of CB2 receptors in B cells and natural killer cells suggests that th is su btype contributes to the potential immunosuppressant and anti-inflammatory effects of cannabinoids (13) . Cannabinoid agonists and antagonists also have been synthesized (14) .
Based on the 119 -THC structure similar compounds such as (-)-1 1-OH-118-THCdimethylheptyl (HU21 0) (15), and nabilone have been developed. These are called "classical cannabinoids''. Highly selective and potent (non classical) cannabinoid receptor agonists, which are structurally distinct from 119-THC have been synthesised. These includeCP55,940 and the novel aminoalkylindol series of compounds (eg WIN 55212-2) (16) . Both classical cannabinoids and nonclassical cannabinoids behave as mixed cannabinoid CB I/CB2 receptor agonists. Although these compounds show differences in intrinsic activity at cannabinoid CB I receptors they generally induce a qualitatively similar profile of behavioral activity across a very broad dose-spectrum. For example, in animal models CP 55,940 produces suppressive effects on operant behaviours at lower dosages, increasing the dose result in hypothermia and eventually catalepsy. Because the major difference in behavioral activity between these compounds relates to potency, rather than efficacy, it may be assumed that the behavioral profile of cannabinoid CB I receptor agonist is mainly determined by the compound's receptor affinity, rather than its intrinsic activity at these receptors. Over a critical level of intrinsic activity they produce a typical cannabinoid-like behavioral profile. A perturbation of the endogenous cannabinoid activities could playa central role in several neuropsychiatric disorders. Such disruptions could occur on several levels: alterations of cannabinoid receptor number, changes in the efficiency with which the receptors transduce signals from the cell surface, changes in the synthesis of endogenous ligands and alterations in the functioning of transporters or metabolism pathways forendocannabinoids. Preclinical and preliminary clinical studies indicate that cannabinoid CB I receptor antagonists (SR 141716A) have suppressive effects on ingestive behavior and body weight reducing effects. In addition, preclinical studies also suggest that these compounds may offer potential treatments for drug addiction, alcohol ism and schizophrenia.
In general, it appears that the more the behavioral (or therapeutic) effect induced by a cannabinoid receptor agonist is situated at the lower side of the dose-spectrum, the more the effect is resistent to blockade by SR 141716A and to the development of tolerance.
It is hypothesized that such differential blockade and tolerance development relates to the existence of different degrees of receptor reserve (spare receptors) and/or receptor-effector coupling. According to this hypothesis, the most sensitive behavioral effects are mediated by receptor populations with a relati vely high degree of receptorreserve/receptor-effector coupling; whereas the least sensitive behavioral effects are mediated by receptor populations with a relatively low degree of receptor reserve/receptor-effector coupling. Th is implies that the therapeutic window of cannabinoid receptor agonists will increase upon repeated administration, as tolerance develops to the sideeffects (occur at relatively high doses), but not to the therapeutic effects that occur at relatively low doses.
Several studies have shown the ability of cannabinoids to inhibit pain. The high concentrations of CB I receptors on primary afferent nociceptors in the dorsal spinal cord and the peripheral CB2 activity have been implicated in the control of pain. Moreover cannabinoids seem to be able to suppress painful spasms and spasticity (17 ) . In an experimental model of Multiple Sclerosis, cannabinoids exert tonic control of spasticity and tremor (18) . The inhibition of the degradation pathways of endocannabinoids by targeting the endocannabinoid transporter or fatty-acid-amide hydrolase degradation the endocannabinoids leads to a significant antispastic effect similar to strong CB I agonism. These compounds do not bind directly to CB I and thus have little inherent psychoactivity. The role of the cannabinoid system in neuroprotection is a source of new interest, but the findings are controversial. Several studies have reported the ability of cannabinoids to protect brain against neuronal injury. The CB I receptor agonist WIN55,212-2 seems to protect the neurons against cerebral ischemic damage in vivo in rats (19) and to protect cultured hippocampal neurons exposed to excitotoxicity induced by Mg 2+ depletion. Conversely, another study described a toxic effect of LiY-THC on cultured hippocampal neurons (20) .
The exact mechanisms of neuroprotection is not known. The ability of the cannabinoid to inhibit ion flux through calcium channels and therefore reduce glutamate release may playa role. Also, the ability to promote hypothermia and antiinflammatory properties (ie. inhibiting the proliferation of lymphocytes and inducing their death by apoptosis) seem to be involved. Furthermore, a non-receptor mediated mechanism for cannabinoid's antioxidant properties could contribute to neuroprotection. The distribution of cannabinoid receptors in the human brain appeared to be highest in the substantia nigra, and globus pallidus. These receptors are likely to beco-Iocalised with dopamine D I/ D2 receptors and adenosine A2a receptors in the basal gangl ia. Th is distribution provides an anatomical substrate for functional interactions between the endocannabinoid system and GABAergic systems and ascending dopaminergic pathways.
In human and animal models a selective loss ofCB I receptors in the striatum is associated with the onset of signs in Huntington's disease before axonal loss is reported. This suggests that some cannabinoid regulation is lost before significant pathology develops.
Studies on small numbers of patients determined that marijuana was not effective in reducing Parkinsonian tremor in some patients. In animal studies, cannabinoids potently inhibit motor behaviour but potentiate GABA-and dopamineinduced catalepsy. Moreover, intrapallidal administration of cannabinoids reduces the uptake of GABA from striatopallidal terminals and inhibits voluntary movement, thus reproducing Parkinson's like symptoms.
If increased cannabinoid tone is a contributing factor in the production of Parkinson 's symptoms, it has been suggested that cannabinoid antagonists may prove therapeutically useful in this disorder. Evidence suggest that the use of cannabinoid antagonists as an adjunct therapy with L-DOPA may reduce the dose ofL-DOPA, thereby decreasi ng the incidence of medication induced dyskinesia.
Moreover, deIta9-tetrahydrocannabinol (THC) seems also to reduce tics in Tourette's Syndrome (21 ) .
The involvement of cannabinoid system in schizophrenia is strongly debated. Clinical signs ofchronic cannabis consumption may also resemble negative symptoms of schizophrenic disorders (22) . Although postulated overthe past two decades, the existence of a specific cannabis-induced psychosis is still not established. Andreasson et al.(23) investigated the association between the level of cannabis intake and the development of schizophrenia during a IS-year follow-up study. The relative risk for schizophrenia among high cannabis consumers was six times higher compared with nonusers. Chopra et al. (24 ) described psychotic reactions following the use of cannabis in a group of marihuana users. Those who had schizoid traits became schizophren ic during the period of cannabis intake. Thacore and Shukla (25) compared the paranoid psychosis associated with long-term cannabis use with paranoid schizophrenia in psychiatric patients and found that cannabis psychosis was characterized by more bizarre behavior, violence, and panic. Gardner et al. investigated the pharmacological relation between the psychotic symptoms of schizophrenic patients and cannabis abuse (26) . They found that~y-THC has dopamine agonist properties especially in dopaminergic projections of the medial forebrain bundles. Furthermore, it was hypothesizes that there should be a tight link of the endogenous cannabinoid system not only to the dopaminergic system but also to the glutamatergic system based upon the observation that regulation ofcannabinoid receptor gene expression in the rat caudate putamen is mediated by glutamate through the N-methyl-daspartate (NMDA) receptor subtype (27) . Emrich et al. (28) stated that cannabis abuse is not merely a stressor for psychotic relapse and exacerbation of schizophrenic syndromes but it may be a subgroup of schizophrenic syndromes pathogenetically related to a functional disturbance of the endogenous cannabinoid/anandamide system. This interesting hypothesis needs to be evaluated further by studies on the basic mechanisms (29-33) of the endogenous cannabinoid system and integration of new investigational tools like selective cannabinoid receptor antagonists into clinical studies. An enhanced understanding of the endogenous cannabinoid system holds promise for novel intervention for a host of neurologiacal and psychiatric problems.
